A Phase 2 Study to Evaluate the Safety, PK, and Exploratory PD of Tildacerfont in Children With CAH

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

An investigation of the safety of Tildacerfont in pediatric subjects with CAH.

Phase 2

Spruce Biosciences